These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 28451690)

  • 1. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
    Kitazawa T; Esaki K; Tachibana T; Ishii S; Soeda T; Muto A; Kawabe Y; Igawa T; Tsunoda H; Nogami K; Shima M; Hattori K
    Thromb Haemost; 2017 Jun; 117(7):1348-1357. PubMed ID: 28451690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
    Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
    J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro.
    Noguchi-Sasaki M; Soeda T; Ueyama A; Muto A; Hirata M; Kitamura H; Fujimoto-Ouchi K; Kawabe Y; Nogami K; Shima M; Kitazawa T
    TH Open; 2018 Jan; 2(1):e96-e103. PubMed ID: 31249933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab promotes factor Xa generation on endothelial cells.
    Fager AM; Ellsworth P; Key NS; Monroe DM; Hoffman M
    J Thromb Haemost; 2024 Jun; 22(6):1605-1615. PubMed ID: 38460838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab.
    Mak S; Marszal A; Matscheko N; Rant U
    MAbs; 2023; 15(1):2149053. PubMed ID: 36453702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
    Østergaard H; Lund J; Greisen PJ; Kjellev S; Henriksen A; Lorenzen N; Johansson E; Røder G; Rasch MG; Johnsen LB; Egebjerg T; Lund S; Rahbek-Nielsen H; Gandhi PS; Lamberth K; Loftager M; Andersen LM; Bonde AC; Stavenuiter F; Madsen DE; Li X; Holm TL; Ley CD; Thygesen P; Zhu H; Zhou R; Thorn K; Yang Z; Hermit MB; Bjelke JR; Hansen BG; Hilden I
    Blood; 2021 Oct; 138(14):1258-1268. PubMed ID: 34077951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
    Yada K; Nogami K
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
    Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
    Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.
    Sampei Z; Igawa T; Soeda T; Funaki M; Yoshihashi K; Kitazawa T; Muto A; Kojima T; Nakamura S; Hattori K
    MAbs; 2015; 7(1):120-8. PubMed ID: 25524207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the N-terminal EGF module of coagulation factor IX in activation of factors IX and X.
    Persson KE
    Scand J Clin Lab Invest Suppl; 2002; 237():13-8. PubMed ID: 12570162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface.
    Ahmad SS; London FS; Walsh PN
    J Thromb Haemost; 2003 Nov; 1(11):2348-55. PubMed ID: 14629468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex.
    Wilkinson FH; Ahmad SS; Walsh PN
    J Biol Chem; 2002 Feb; 277(8):5734-41. PubMed ID: 11714704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex.
    Kerschbaumer RJ; Riedrich K; Kral M; Varadi K; Dorner F; Rosing J; Scheiflinger F
    J Biol Chem; 2004 Sep; 279(39):40445-50. PubMed ID: 15265864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.